|
|
|
(Journal Article): Glucagon-like peptide-l (7-37) suppresses hyperglyeaemia in rats.
Hendrick GK, Gjinovci A, Baxter LA, Mojsov S, Wollheim CB, Habener JF, Weir GC (Joslin Diabetes Center, Boston, MA 02215.)
IN:
Metabolism
1993; 42(1):1-6
Impact Factor(s) of Metabolism: 2.143 (2004), 2.013 (2003), 1.931 (2001)
Fulltext:
HTML
ABSTRACT: Glucagon-like peptide-(GLP) I-(7-37) is an endogenous hormone that has recently been demonstrated to be a potent insulin secretagogue. In these studies, GLP was administered during oral and intravenous (IV) glucose tolerance tests (OGTT and IVGTT, respectively) to determine whether this peptide could enhance postprandial insulin levels and thus reduce glycemic excursions. Surprisingly, during OGTT, GLP administration did not augment insulin secretion; however, GLP administration resulted in significantly lower glycemic excursions. In fasted rats, glycemic excursions were significantly reduced 10 and 20 minutes after receiving GLP (P < .001). Fed rats that received GLP had virtually no initial increase in plasma glucose level after administration of oral glucose. During IVGTT, glucose alone increased insulin levels eightfold, while administration of both glucose and GLP resulted in a 15-fold increase (P < .001). These IVGTT data support previous studies that show GLP to be a potent and glucose-dependent insulin secretagogue. Furthermore, all of these studies suggest that GLP reduces postprandial glycemic excursion and thus may be useful in the treatment of non-insulin-dependent diabetes mellitus.
TYPE OF PUBLICATION: Original article
Articles citing this article:
|
Respond
on this Journal Article!
Hint: Your Response should directly apply to Glucagon-like peptide-l (7-37) suppresses hyperglyeaemia in rats..
Please check, if this context applies best to your contribution. Otherwise click HERE to change to the appropriate
subject area. The actual subject area is Oral.
|
|
|
|
|
